OncLive.com

🤔Looking for clinical answers about multiple myeloma and the oncology field? Good news, COMMENT on this post with any questions you have and @JoshuaRichterMD of @TischCancer will answer them in OncLive's new #AskMeAnything series‼️ 💥 From bispecific antibodies to previewing #EHA2026, NOTHING is off the table! Drop your questions in the comments section of this post by May 25th‼️ #mmsm #oncology #cancer #medtwitter @MountSinaiNYC

WATCH 👀: Rebecca Silbermann, MD, MMS, of @OHSUNews outlines key trial design considerations in multiple myeloma, including supportive care measures and end point selection. See the whole video here ➡️: hubs.li/Q04j1qV10 #mmsm #oncology

WATCH 👀: @lore_gruenbaum of @BloodCancerUtd discusses alternative treatments to BTK inhibitors like bispecific antibodies and CAR T-cell therapy in mantle cell lymphoma. See the whole video here ➡️: hubs.li/Q04j17250 #lymsm #oncology

🤔 “If we say, ‘Why not just do ADT alone with nothing else?’ The answer is, if we do that, your life would be shorter by 40% or 50%,” said @AlanBryce9 of @cityofhope during a recent OncLive Peer Exchange, where prostate cancer experts discussed the evolving role of treatment intensification in mCSPC. Read more here ➡️: hubs.li/Q04h_Kvg0 #pcsm #oncology

🧬 Can’t attend #ASCO26 this weekend? The EGFR Channel has you covered! Stay up to date with the latest findings in EGFRm NSCLC with rapid, curated updates on key abstracts, emerging data, and clinical insights shared throughout the meeting. 🔗 Explore now: hubs.li/Q04gpvVG0 #EGFR #NSCLC #LungCancer #Oncology #MedTwitter #OncTwitter #CancerResearch

David Y.T. Chen, MD, FACS, discusses how AI is reshaping surgical approaches in GU oncology during #AUA26 #oncology #AI #GUcancer Check out all of our coverage of the meeting here: hubs.li/Q04j6kqW0

🚨 Newly published in @NEJM: HERIZON-GEA-01 data show #zanidatamab plus chemotherapy ± tislelizumab significantly improved survival in HER2-positive GEA. 📊 Our latest coverage features exclusive insights from Geoffrey Ku, MD, of @MSKCancerCenter on the implications of this landmark publication, plus a preview of upcoming PD-L1 subgroup analyses set to be presented at #ASCO26. 🔬 Read more here 📰: onclive.com/view/zanidatam… #gicsm #oncology #gastriccancer #esophagealcancer

BREAKING🚨: The FDA has approved pivekimab sunirine for the treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm #oncology Read more: onclive.com/view/fda-appro…

🚀 Another next-gen ALK inhibitor moves closer to the clinic. The FDA has granted Priority Review to neladalkib (NVL-655) for patients with TKI-pretreated ALK+ NSCLC, backed by ALKOVE-1 data showing durable systemic and intracranial activity in heavily pretreated disease. 🧠📊 Read more ➡️ onclive.com/view/fda-grant… #LungCancer #NSCLC #ALK #TargetedTherapy #PrecisionOncology #Oncology #MedTwitter

Thomas Powles, MBBS, MRCP, MD, Brian Rini, MD, FASCO, and Elizabeth Plimack, MD, MS, FASCO, tackle first-line decision-making in advanced RCC, from tumor biology and IMDC risk stratification to emerging therapies and dose optimization in this 13-episode OncLive News Network series. Watch now: hubs.li/Q04dqmQf0 #RenalCellCarcinoma #kcsm #Oncology @tompowles1 @NHSBartsHealth @brian_rini @VUMChealth @ERPlimackMD @FoxChaseCancer

The @US_FDA extended the review period for camizestrant plus a CDK4/6 inhibitor in hormone receptor–positive breast cancer with an emergent ESR1 mutation. @jane_meisel @AlexisLeVee @drsarahsam @WinshipAtEmory @EmoryMedicine @UCLAHealth #bcsm #oncology onclive.com/view/fda-exten…

Building a pancreatic cancer vaccine is far more complex than simply “training” the immune system. 🧬 Paul E. Oberstein, MD, of @nyulangone explains how researchers identify tumor-specific neoantigens and why developing personalized cancer vaccines requires extensive sequencing, computation, and immune profiling. 🔬 Watch the full video here 🎥 #pancsm #PancreaticCancer #oncology

That’s a wrap on yesterday’s studio session 🎬 Huge thanks to Joshua Richter for stopping by HQ and sharing his insights on the evolving multiple myeloma landscape and key #EHA2026 updates.🔬 Be sure to check out the full AMA on youtube and podcast episode when they drop later this week 🎧👀 #mmsm #myeloma #EHA26 #AskMeAnything #OncLiveAMA

WATCH 👀: Michael Mauro, MD, of @MSKCancerCenter details the @US_FDA approval of the small-molecule formulation of dasatinib and other alternate TKI formulations in CML. See the whole video here ➡️: hubs.li/Q04hYWtV0 #leusm #oncology

ICYMI 👀: Luhua (Michael) Wang, MD, of @UTMDAnderson discussed the @US_FDA approval of brexu-cel in MCL and what to know about CAR T-cell therapy in clinical practice. See the whole conversation here 📰: hubs.li/Q04hZQc_0 #lymsm #oncology

📰 A 2-year freedom from biochemical recurrence rate of 90.3% was shown for nivolumab plus SOC in grade group 5 prostate cancer, encouraging trial investigators. Read more here ➡️: hubs.li/Q04h-GCZ0 #pcsm #oncology

🔬 Primary end points for the phase 2 SATEEN trial evaluating post–T-DXd sacituzumab govitecan plus trastuzumab in HER2+ metastatic breast cancer, providing valuable insight. Full details 📰: hubs.li/Q04hZSNQ0 #bcsm #oncology

⚛️ Numerical OS benefits were shown for capivasertib plus fulvestrant compared with placebo plus fulvestrant in PIK3CA/AKT1/PTEN-altered advanced breast cancer, signaling promise to phase 3 trial investigators. Read more here 📰: hubs.li/Q04hZSZd0 #bcsm #oncology

WATCH: @DrKEMcCann discusses the clinical utility of T-DXd followed by THP for HER2-positive early breast cancer. @UCSanDiego #bcsm #oncology onclive.com/view/dr-mccann…

💥 @US_FDA has approved zenocutuzumab for the treatment of adult patients with NRG1 fusion–positive advanced, unresectable, or metastatic CCA, based on the phase 1/2 eNRGy trial. Read more here 📈: hubs.li/Q04hYTJF0 #oncology